Search - tctmd.com

Displaying 401 - 415 of 415

Sort: Relevancy | Date

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

News Daily News

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

L.A. McKeown

March 12, 2012

News Daily News

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

L.A. McKeown

March 12, 2012

News Daily News

Cerebrovascular Event Risk Highest in First 24 Hours After TAVR

March 06, 2012

News Daily News

El mayor riesgo de episodios cerebrovasculares se da en las primeras 24 horas posteriores a un RVAT

March 06, 2012

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

News Daily News

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Caitlin E. Cox

September 14, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

News Daily News

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

Caitlin E. Cox

August 10, 2011

News Conference News

PROTECTION-AMI: Experimental Agent Does Not Prevent Reperfusion Injury

Caitlin E. Cox

April 05, 2011

News Daily News

Stent Thrombosis, Major Bleeding Rare with Sirolimus-Eluting Stents

March 21, 2011

News Daily News

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

Jason Kahn

February 09, 2011

News Industry News

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

January 04, 2011

News Daily News

Dabigatran an Alternative to Warfarin for Stroke Prevention in A-Fib Patients

Kim Dalton

September 03, 2009

Advertisement

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

Cerebrovascular Event Risk Highest in First 24 Hours After TAVR

El mayor riesgo de episodios cerebrovasculares se da en las primeras 24 horas posteriores a un RVAT

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

PROTECTION-AMI: Experimental Agent Does Not Prevent Reperfusion Injury

Stent Thrombosis, Major Bleeding Rare with Sirolimus-Eluting Stents

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

Dabigatran an Alternative to Warfarin for Stroke Prevention in A-Fib Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content